NICE - Endorsed Technology Appraisals 2025/2026
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
2025/2026
The following technology appraisals have been endorsed during 2025/26. Information on technology appraisals endorsed in previous years can be found on the homepage.
March 2026
TA1130 - Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer
TA1131 - Obinutuzumab with mycophenolate mofetil for treating lupus nephritis
TA1129 - Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy This guidance updates and replaces NICE Technology Appraisal TA673, endorsed by the DoH in March 2026.
February 2026
TA1128 - Targeted-release budesonide for treating primary IgA nephropathy This guidance updates and replaces NICE Technology Appraisal TA937, endorsed by the DoH in January 2024.
TA1121 - Acoramidis for treating transthyretin amyloidosis with cardiomyopathy
TA1120 - Avelumab with axitinib for untreated advanced renal cell carcinoma ‘Note this guidance updates and replaces NICE Technology Appraisal TA645, endorsed by the DoH in September 2020’.
TA1119 - Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia ‘Note this guidance updates and replaces NICE Technology Appraisal TA663, endorsed by the DoH in January 2021’.
January 2026
TA1115 - Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy
December 2025
- TA1114 - Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments
- TA1113 - Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma
- TA1110 - Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer Note this guidance updates and replaces NICE Technology Appraisal TA721, endorsed by the DoH in September 2021.
November 2025
- TA1109 - Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
- TA1108 - Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
- TA1107 - Delgocitinib for treating moderate to severe chronic hand eczema
- TA1106 - Cabotegravir for preventing HIV-1 in adults and young people
- TA1103 - Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
- TA1101 - Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over
October 2025
- TA1099 - Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy
- TA1098 - Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable
- TA1097 - Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable
September 2025
- TA1096 - Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis
- TA1095 - Guselkumab for previously treated moderately to severely active Crohn's disease
- TA1094 - Guselkumab for treating moderately to severely active ulcerative colitis
- TA1093 - Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over
- TA1092 - Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer
- TA1091 - Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments
- TA1090 - Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma
- TA1088 - Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over
- TA1087- Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen
August 2025
- TA1086 - Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence
- TA1085 - Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over
- TA1081 - Zanubrutinib for treating relapsed or refractory mantle cell lymphoma
- TA1080 - Mirikizumab for preciously treated moderately to severely active Crohn's disease
- TA1079 - Fruquintinib for previously treated metastatic colectoral cancer
July 2025
- TA1077 - Nemolizub for treating moderate to severe atopic dermatitis in people in 12 years and over
- TA1075 - Dapagliflozin for treating chronic kidney disease ‘Note this guidance updates and replaces NICE Technology Appraisal TA775, endorsed by the DoH in March 2022’.
- TA1074 - Sparsentan for treating primary IgA nephropathy
- TA1073 - Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodiesCE
- TA1071 - Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerNote this guidance updates and replaces NICE Technology Appraisal TA823, endorsed by the DoH in October 2022’
June 2025
- TA1070 - Spesolimab for treating generalised pustular psoriasis flares
- TA1069 - Efgartigimod for treating antibody-positive generalised myasthenia gravis
- TA1067 - Linzagolix for treating symptoms of endometriosis
- TA1066 - Somapacitan for treating growth hormone deficiency in people 3 to 17 years
- TA1065 - Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
- TA1064 - Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | NICE Note this guidance updates and replaces NICE Technology Appraisal TA963, endorsed by the DoH in April 2024
- TA1063 - Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment | Guidance | NICE
May 2025
- TA1062 - Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor
- TA 1060 - Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer | Guidance | NICE
- TA1059 - Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma | Guidance | NICE
- TA1057 - Relugolix–estradiol–norethisterone for treating symptoms of endometriosis | Guidance | NICE
- TA1056 - Molnupiravir for treating COVID-19
- TA1055 - Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
- TA1054 - Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over
- TA1053 - Cladribine for treating active relapsing forms of multiple sclerosis
April 2025